<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03083067</url>
  </required_header>
  <id_info>
    <org_study_id>SF2016-1-4071</org_study_id>
    <nct_id>NCT03083067</nct_id>
  </id_info>
  <brief_title>Salvational Intervention for Reducing AECOPD Under Severe Air Pollution</brief_title>
  <acronym>SIRCAP</acronym>
  <official_title>A Prospective Study of Salvational Intervention With ICS/LABA for Reducing Chronic Obstructive Pulmonary Disease Exacerbation Under Severe Air Pollution (SIRCAP) in Beijing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University Shougang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People’s Hospital of Beijing Daxing District</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Jingmei Group General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Miyun Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital of Shunyi District Beijing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Luhe Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Civil Aviation General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Jishuitan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aerospace 731 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Changping Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, prospective, randomized and standard treatment parallel control
      clinical trial.A total of 764 stable COPD patients according to GOLD will be recruited and
      equally divided into two parallel groups, salvational intervention group (SI group) and
      control group (CT group).On the foundation of basic medicine, inhaled ICS/LABA will be used
      as an intervention drug for patients in SI group on severe air pollution days. It is aimed to
      evaluate whether this novel treatment strategy will decrease the frequency of AECOPD per
      year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, prospective, randomized and standard treatment parallel control
      clinical trial. A total of 764 stable COPD patients with history of exacerbation according to
      GOLD will be recruited and equally divided into two parallel groups, salvational intervention
      group (SI group) and control group (CT group). The randomization is stratified by medical
      center and the random code is designed in a 1:1 ratio. The Department of Respiratory and
      Critical Care of Peking University First Hospital is responsible for this research. Other 10
      units participating in the study include Peking University Shougang Hospital, People's
      Hospital of Beijing Daxing District, Beijing Jingmei Group General Hospital, Beijing Miyun
      Hospital, Beijing Changping Hospital, The Hospital of Shunyi District Beijing, Beijing Luhe
      Hospital Capital Medical University, Civil Aciation General Hospital, Beijing Jishuitan
      Hospital and Aerospace 731 Hospital. These 11 centers approximately cover area from urban to
      suburbs in Beijing.

      Inhaled tiotropium bromide(18ug), budesonide/formoterol（160ug/4.5ug）or tiotropium
      bromide(18ug)+ budesonide/formoterol （160ug/4.5ug）will be used as basic medicine. On the
      foundation of basic medicine, inhaled budesonide/formoterol（160ug/4.5ug）will be used as an
      intervention drug for patients in SI group. When air quality index (AQI) is above 200, they
      will temporary add one inhalation of budesonide/formoterol（160ug/4.5ug）twice a day until the
      third day after AQI drops below 200. CT group maintains the original treatment. Besides
      baseline, patients will be formally visited 4 or 5 times during this trial: before
      randomization (for those who need pharmacological washout) and every six months after
      randomization.

      Primary outcome is the frequency of AECOPD per year, which is defined as the frequency of
      AECOPD/the number of patients/year. Secondary outcomes include the number of unplanned
      outpatient visits, emergency medical visits, hospitalization, medical expense and mortality
      caused by AECOPD per year.

      The study protocol has been approved by the Peking University First Hospital Institutional
      Review Board (IRB) (2016[1032]). Any protocol modifications will be submitted for the IRB
      review and approval.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the frequency of exacerbation of COPD per year</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the number of unplanned outpatient visits caused by exacerbation of COPD per year</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of unplanned emergency medical visits caused by exacerbation of COPD per year</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of unplanned hospitalization caused by exacerbation of COPD per year</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the cost of unplanned medical expense caused by exacerbation of COPD per year</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of unplanned mortality caused by exacerbation of COPD per year</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">764</enrollment>
  <condition>COPD Exacerbation</condition>
  <condition>Air Pollution</condition>
  <arm_group>
    <arm_group_label>Salvational intervention(SI) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug on the foundation of original treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control(CT) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CT group maintain the original treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/formoterol</intervention_name>
    <description>On the foundation of basic treatment strategies, inhaled budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug for patients in PIC group. When air quality index (AQI) is above 200, they will temporary add one inhalation of budesonide/formoterol（160ug/4.5ug）twice a day until the third day after AQI drops below 200.</description>
    <arm_group_label>Salvational intervention(SI) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium bromide</intervention_name>
    <description>Inhaled tiotropium bromide(18ug) will be used as routine medicine according to doctor's advice.</description>
    <arm_group_label>Salvational intervention(SI) group</arm_group_label>
    <arm_group_label>Control(CT) group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. aged at 40-80 years old;

          2. spirometry confirmed diagnose of COPD with at least once exacerbation before, and
             stable for at least three months;

          3. quit smoking for more than six months;

          4. be able to engage in daily activities;

          5. have willing to participate in this study, follow the research program and have the
             ability to sign the informed consent;

          6. Beijing residents;

          7. can be contacted;

        Exclusion Criteria:

          1. history of asthma, lung cancer, active pulmonary tuberculosis, bronchiectasis, diffuse
             lung disease (interstitial pneumonia, pulmonary sarcoidosis, occupational lung
             disease, sarcoidosis et al) and pleural disease;

          2. history of lobectomy and / or lung transplantation;

          3. predicted life expectancy less than 3 years;

          4. history of severe psychiatric illnesses, mental disorders, neurological disorders,
             malignant tumors, chronic liver disease, heart failure, autoimmune diseases, chronic
             kidney disease;

          5. Never engage in outdoor activities;

          6. plan to move out of Beijing in 3 years

          7. Plan to carry out an indoor redecoration during the study;

          8. Alcoholism, drug abuse or abuse of toxic solvents;

          9. Allergic to the study drug or its ingredients, or have a clear contraindication of it;

         10. Participation in another clinical trial;

         11. Cannot finish long term follow-up or poor compliance;

         12. Do not provide consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guangfa Wang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guangfa Wang, MD</last_name>
    <phone>+86 13810644029</phone>
    <email>wangguangfa@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tianyu Zhou, PhD</last_name>
    <phone>+86 18813186274</phone>
    <email>zty2712@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tianyu Zhou, PhD</last_name>
      <email>zty2712@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yijue Zhong, PhD</last_name>
      <email>zhongyijue1985@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Aerospace 731 Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fengzhen Zhang</last_name>
      <email>zfz731hx@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Changping Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiangxin Li</last_name>
      <email>13691008082@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Jingmei Group General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunxiao Yu</last_name>
      <email>13811384503@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Jishuitan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guoguang Xia</last_name>
      <email>guoguangxia1958@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Luhe Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenyang Xu</last_name>
      <email>azhenyang@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Miyun Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Senlin Wang</last_name>
      <email>13701387739@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Civil Aviation General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaosen Qian</last_name>
      <email>qian186@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Shougang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pingchao Xiang</last_name>
      <email>xpcemail@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Beijing Daxing District</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongxiang Zhang</last_name>
      <email>zyx8669@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Hospital of Shunyi District Beijing</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xisheng Chen</last_name>
      <email>syhx2011@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Guangfa Wang</investigator_full_name>
    <investigator_title>Prof. &amp; MD.</investigator_title>
  </responsible_party>
  <keyword>AECOPD</keyword>
  <keyword>air pollution</keyword>
  <keyword>COPD</keyword>
  <keyword>salvational Intervention</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

